Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11660637 | 0.99 | BACE1 (0.49) | BACE1MMP2NPY1RNPY2RNPY4R | |
| SCHEMBL11660631 | 0.99 | BACE1 (0.49) | BACE1MMP2NPY1RNPY2RNPY4R | |
| SCHEMBL24270257 | 0.89 | MMP2 (0.52) | BACE1MMP2NPY1RNPY2RNPY4R | |
| SCHEMBL30688844 | 0.89 | MMP2 (0.55) | BACE1MMP2NPY1RNPY2RNPY4R | |
| SCHEMBL31602281 | 0.89 | GNPAT (0.57) | MMP2 | |
| SCHEMBL29389091 | 0.89 | MMP2 (0.51) | BACE1MMP2NPY1RNPY2RNPY4R | |
| SCHEMBL29679650 | 0.88 | ERAP2 (0.55) | BACE1MMP2 | |
| SCHEMBL10520779 | 0.88 | GHSR (0.54) | BACE1MMP2 | |
| SCHEMBL30799638 | 0.86 | MMP2 (0.56) | BACE1MMP2NPY1RNPY2RNPY4R | |
| SCHEMBL31602283 | 0.86 | CTSL (0.55) | MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | BCN PEPTIDES, S.A. (ES) | 2025-05-13 | — | — | US | claimed |
| EP-4583873-A2 | GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120131956-A | Use of growth hormone inhibitors, and pharmaceutical compositions, formulations, and devices containing growth hormone inhibitors | 中山大学中山眼科中心 | 2025-06-13 | — | — | CN | disclosed |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | BCN PEPTIDES, S.A. (ES) | 2025-05-13 | — | — | US | disclosed |
| CN-111886336-B | CASZ compositions and methods of use | 加利福尼亚大学董事会 | 2025-05-02 | — | — | CN | disclosed |
| CN-113652411-B | Cas9 protein, gene editing system containing Cas9 protein and application | 复旦大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-114981296-B | Recombinant GBD-SSTad-SSTad protein and preparation method and application thereof | 优思药业有限责任公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024054785-A2 | GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-112020560-B | RNA-edited CRISPR/Cas effect protein and system | 中国农业大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-111388680-B | Application of polypeptide complex as polypeptide or protein drug carrier, method and fusion protein complex thereof | 中国科学院天津工业生物技术研究所 | 2024-01-05 | — | — | CN | disclosed |
| CN-114814241-A | Use of protein and screening method | 广东省农业科学院动物科学研究所 | 2022-07-29 | — | — | CN | disclosed |
| CN-111617250-B | Multi-ligand drug couplet and application thereof | 同宜医药（苏州）有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114621982-A | Biosynthesis method of geranyl diphosphate and application of geranyl diphosphate in preparation of cannabis compounds | 嘉兴欣贝莱生物科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114555792-A | Recombinant engineered, lipase/esterase deficient mammalian cell lines | 伊莱利利公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114480340-A | Halophilic choline kinase mutant and application thereof | 郑州大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20220135640-A1 | CORTISTATIN OR AN ANALOGUE THEREOF AS A PHARMACEUTICALLY ACTIVE AGENT IN LATENT FORM | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-05-05 | — | — | US | disclosed |
| CN-114410675-A | Recombinant strain containing enol kinase gene and isopentenyl phosphate kinase gene and application thereof in production of terpenoid | 深圳先进技术研究院 | 2022-04-29 | — | — | CN | disclosed |
| CN-108135993-B | Pestivirus vaccine for congenital tremor | 贝林格尔·英格海姆维特梅迪卡有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112533936-B | Method for purifying peptide using sulfonic acid compound | 长濑产业株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-109311910-B | Tacrolimus conjugates, compositions thereof, and uses thereof | 杜兰教育基金委员会 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | GHSR, GIPR, GHRHR | BACE1 2464/4885MMP2 2068/4885NPY1R 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.